Literature DB >> 29500500

[B cells in head and neck oncology].

P J Schuler1, C Brunner2, T K Hoffmann2.   

Abstract

As immunotherapy is becoming increasingly important in the treatment of head and neck cancer, a fundamental understanding of the immunological relationships in the tumor microenvironment is required. The importance of tumor-infiltrating B cells (TIL-B) has been largely neglected so far. In the current literature, however, a significant influence of B cells on tumor growth is described, so that this cell population is now also perceived as a therapeutic target structure. Regulatory B cells (Breg) represent a subset of B cells with immunosuppressive properties. In addition to the secretion of IL-10, Breg can be defined by their ability to produce adenosine. Adenosine is known as an immunosuppressive messenger in the tumor microenvironment whose effect can be prevented by immunotherapeutic approaches. Understanding the tumor immunological relationships, including the different B‑cell functions, can help to effectively combine standard approaches including surgery or radiochemotherapy with immunotherapy. In the present article, recent findings on B cells and adenosine in head and neck cancer are described.

Entities:  

Keywords:  Adenosine; B-lymphocyte subsets; B-lymphocytes; Head and neck neoplasms; Regulatory B cells

Mesh:

Year:  2018        PMID: 29500500     DOI: 10.1007/s00106-018-0494-5

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  53 in total

1.  Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Authors:  Deepak Mittal; Arabella Young; Kimberley Stannard; Michelle Yong; Michele W L Teng; Bertrand Allard; John Stagg; Mark J Smyth
Journal:  Cancer Res       Date:  2014-07-01       Impact factor: 12.701

2.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

3.  Adenosine metabolism of human mesenchymal stromal cells isolated from patients with head and neck squamous cell carcinoma.

Authors:  Patrick J Schuler; Anna-Maria Westerkamp; Benjamin A Kansy; Kirsten Bruderek; Philip A Dissmann; Claudia A Dumitru; Stephan Lang; Edwin K Jackson; Sven Brandau
Journal:  Immunobiology       Date:  2016-01-30       Impact factor: 3.144

4.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

5.  Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

6.  CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.

Authors:  Bruno G Leclerc; Roxanne Charlebois; Guillaume Chouinard; Bertrand Allard; Sandra Pommey; Fred Saad; John Stagg
Journal:  Clin Cancer Res       Date:  2015-08-07       Impact factor: 12.531

7.  Adenosine production by human B cells and B cell-mediated suppression of activated T cells.

Authors:  Zenichiro Saze; Patrick J Schuler; Chang-Sook Hong; Dongmei Cheng; Edwin K Jackson; Theresa L Whiteside
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

8.  Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.

Authors:  P J Schuler; Z Saze; C-S Hong; L Muller; D G Gillespie; D Cheng; M Harasymczuk; M Mandapathil; S Lang; E K Jackson; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 9.  B cell regulation in cancer and anti-tumor immunity.

Authors:  Anushruti Sarvaria; J Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2017-06-19       Impact factor: 11.530

Review 10.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.